Aripiprazole in prodromal psychosis: A case report

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 10, Issue 2, 2008, Pages 162-

  Bharadwaj, Balaji ^a   Bhargavaraman, R P ^a   Ravi, P R ^a   Math, Suresh Bada ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE;

ADOLESCENT; CASE REPORT; DRUG DOSE INCREASE; DRUG TOLERABILITY; HUMAN; LETTER; MALE; PRODROMAL PSYCHOSIS; PSYCHOSIS;

EID: 45749144034     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v10n0213c     Document Type: Letter

References (6)

1. Haroun N, Dunn L, Haroun A, et al. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull 2006;32:166-178
2. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002;159:863-865
3. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921-928
4. Woods SW, Breier A, Zipursky RB, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003;54:453-464
5. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia: systematic review. Br J Psychiatry 2006;189:102-108
6. Phillips LJ, Leicester SB, O'Dwyer LE, et al. The PACE Clinic: identification and management of young people at "ultra" high risk of psychosis. J Psychiatr Pract 2002;8:255-269